{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,2,10]],"date-time":"2024-02-10T00:19:42Z","timestamp":1707524382350},"reference-count":20,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021,9,29]]},"DOI":"10.7759\/cureus.18380","type":"journal-article","created":{"date-parts":[[2021,9,29]],"date-time":"2021-09-29T13:59:38Z","timestamp":1632923978000},"source":"Crossref","is-referenced-by-count":0,"title":["The Rarest of the Rare: A Case of BAP1-Mutated Primary Peritoneal Mesothelioma"],"prefix":"10.7759","author":[{"given":"Aanchal","family":"Gupta","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alisa","family":"Vasileva","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sukesh","family":"Manthri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.21037\/tlcr.2017.05.03","article-title":"BAP1, a tumor suppressor gene driving malignant mesothelioma","volume":"6","author":"Cheung M","year":"2017","unstructured":"Cheung M, Testa JR. BAP1, a tumor suppressor gene driving malignant mesothelioma. Transl Lung Cancer Res. 2017, 6:270-8. 10.21037\/tlcr.2017.05.03","journal-title":"Transl Lung Cancer Res"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.21037\/atm.2017.04.29","article-title":"Mesothelioma: recent highlights","volume":"5","author":"Carbone M","year":"2017","unstructured":"Carbone M, Yang H. Mesothelioma: recent highlights. Ann Transl Med. 2017, 5:238. 10.21037\/atm.2017.04.29","journal-title":"Ann Transl Med"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.21037\/tlcr.2019.11.15","article-title":"Mesothelioma developing in carriers of inherited genetic mutations","volume":"9","author":"Yoshikawa Y","year":"2020","unstructured":"Yoshikawa Y, Emi M, Nakano T, Gaudino G. Mesothelioma developing in carriers of inherited genetic mutations. Transl Lung Cancer Res. 2020, 9:S67-76. 10.21037\/tlcr.2019.11.15","journal-title":"Transl Lung Cancer Res"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1038\/ng.912","article-title":"Germline BAP1 mutations predispose to malignant mesothelioma","volume":"43","author":"Testa JR","year":"2011","unstructured":"Testa JR, Cheung M, Pei J, et al.. Germline BAP1 mutations predispose to malignant mesothelioma. Nat Genet. 2011, 43:1022-5. 10.1038\/ng.912","journal-title":"Nat Genet"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1097\/JTO.0000000000000471","article-title":"High Incidence of Somatic BAP1 alterations in sporadic malignant mesothelioma","volume":"10","author":"Nasu M","year":"2015","unstructured":"Nasu M, Emi M, Pastorino S, et al.. High Incidence of Somatic BAP1 alterations in sporadic malignant mesothelioma. J Thorac Oncol. 2015, 10:565-76. 10.1097\/JTO.0000000000000471","journal-title":"J Thorac Oncol"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.21037\/atm.2017.03.96","article-title":"Malignant peritoneal mesothelioma: a review","volume":"5","author":"Kim J","year":"2017","unstructured":"Kim J, Bhagwandin S, Labow DM. Malignant peritoneal mesothelioma: a review. Ann Transl Med. 2017, 5:236. 10.21037\/atm.2017.03.96","journal-title":"Ann Transl Med"},{"key":"ref7","article-title":"Patterns in the incidence, mortality and survival of malignant pleural and peritoneal mesothelioma, New South Wales, 1972-2009","volume":"40","author":"Soeberg MJ","year":"2016","unstructured":"Soeberg MJ, Creighton N, Currow. Patterns in the incidence, mortality and survival of malignant pleural and peritoneal mesothelioma, New South Wales, 1972-2009. ANZ J Pub Health. 2016, 40:255-62.","journal-title":"ANZ J Pub Health"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1097\/PAT.0000000000000181","article-title":"Diffuse mesothelioma of the peritoneum: correlation between histological and clinical parameters and survival in 73 patients","volume":"46","author":"Liu S","year":"2014","unstructured":"Liu S, Staats P, Lee M, Alexander HR, Burke AP. Diffuse mesothelioma of the peritoneum: correlation between histological and clinical parameters and survival in 73 patients. Pathology. 2014, 46:604-9. 10.1097\/PAT.0000000000000181","journal-title":"Pathology"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1038\/modpathol.3800067","article-title":"Diffuse malignant mesothelioma of the peritoneum and pleura, analysis of markers","volume":"17","author":"Trupiano JK","year":"2004","unstructured":"Trupiano JK, Geisinger KR, Willingham MC, Manders P, Zbieranski N, Case D, Levine EA. Diffuse malignant mesothelioma of the peritoneum and pleura, analysis of markers. Mod Pathol. 2004, 17:476-81. 10.1038\/modpathol.3800067","journal-title":"Mod Pathol"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1093\/oxfordjournals.aje.a009093","article-title":"Analysis of current trends in United States mesothelioma incidence","volume":"145","author":"Price B","year":"1997","unstructured":"Price B. Analysis of current trends in United States mesothelioma incidence. Am J Epidemiol. 1997, 145:211-8. 10.1093\/oxfordjournals.aje.a009093","journal-title":"Am J Epidemiol"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.21037\/tlcr.2018.10.04","article-title":"Malignant peritoneal mesothelioma: a review","volume":"7","author":"Broeckx G","year":"2018","unstructured":"Broeckx G, Pauwels P. Malignant peritoneal mesothelioma: a review. Transl Lung Cancer Res. 2018, 7:537-42. 10.21037\/tlcr.2018.10.04","journal-title":"Transl Lung Cancer Res"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1186\/s12967-018-1559-7","article-title":"Detecting germline BAP1 mutations in patients with peritoneal mesothelioma: benefits to patient and family members","volume":"16","author":"Kittaneh M","year":"2018","unstructured":"Kittaneh M, Berkelhammer C. Detecting germline BAP1 mutations in patients with peritoneal mesothelioma: benefits to patient and family members. J Transl Med. 2018, 16:194. 10.1186\/s12967-018-1559-7","journal-title":"J Transl Med"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1093\/carcin\/bgu227","article-title":"Mesothelioma patients with germline BAP1 mutations have 7-fold improved long-term survival","volume":"36","author":"Baumann F","year":"2015","unstructured":"Baumann F, Flores E, Napolitano A, et al.. Mesothelioma patients with germline BAP1 mutations have 7-fold improved long-term survival. Carcinogenesis. 2015, 36:76-81. 10.1093\/carcin\/bgu227","journal-title":"Carcinogenesis"},{"key":"ref14","article-title":"BAP1 tumor predisposition syndrome","author":"Pilarski R","year":"2016","unstructured":"Pilarski R, Rai K, Cebulla C, et al.. BAP1 tumor predisposition syndrome. Gene Reviews. Adam MP, Ardinger HH, Pagon RA, et al. (ed): University of Washington, Seattle; 2016."},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1111\/cge.12630","article-title":"Comprehensive review of BAP1 tumor predisposition syndrome with report of two new cases","volume":"89","author":"Rai K","year":"2016","unstructured":"Rai K, Pilarski R, Cebulla CM, Abdel-Rahman MH. Comprehensive review of BAP1 tumor predisposition syndrome with report of two new cases. Clin Genet. 2016, 89:285-94. 10.1111\/cge.12630","journal-title":"Clin Genet"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-2600(18)30420-X","article-title":"Ipilimumab and nivolumab in the treatment of recurrent malignant pleural mesothelioma (INITIATE): results of a prospective, single-arm, phase 2 trial","volume":"7","author":"Disselhorst MJ","year":"2019","unstructured":"Disselhorst MJ, Quispel-Janssen J, Lalezari F, et al.. Ipilimumab and nivolumab in the treatment of recurrent malignant pleural mesothelioma (INITIATE): results of a prospective, single-arm, phase 2 trial. Lancet Respir Med. 2019, 7:260-70. 10.1016\/S2213-2600(18)30420-X","journal-title":"Lancet Respir Med"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(18)30765-4","article-title":"Nivolumab or nivolumab plus ipilimumab in patients with relapsed malignant pleural mesothelioma (IFCT-1501 MAPS2): a multicentre, open-label, randomised, non-comparative, phase 2 trial","volume":"20","author":"Scherpereel A","year":"2019","unstructured":"Scherpereel A, Mazieres J, Greillier L, et al.. Nivolumab or nivolumab plus ipilimumab in patients with relapsed malignant pleural mesothelioma (IFCT-1501 MAPS2): a multicentre, open-label, randomised, non-comparative, phase 2 trial. Lancet Oncol. 2019, 20:e132. 10.1016\/S1470-2045(18)30765-4","journal-title":"Lancet Oncol"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2020.103040","article-title":"Efficacy of nivolumab and ipilimumab in patients with malignant pleural mesothelioma is related to a subtype of effector memory cytotoxic T cells: translational evidence from two clinical trials","volume":"62","author":"Mankor JM","year":"2020","unstructured":"Mankor JM, Disselhorst MJ, Poncin M, Baas P, Aerts JG, Vroman H. Efficacy of nivolumab and ipilimumab in patients with malignant pleural mesothelioma is related to a subtype of effector memory cytotoxic T cells: translational evidence from two clinical trials. EBioMedicine. 2020, 62:103040. 10.1016\/j.ebiom.2020.103040","journal-title":"EBioMedicine"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2000.18.23.3912","article-title":"Phase II study of vinorelbine in patients with malignant pleural mesothelioma","volume":"18","author":"Steele JP","year":"2000","unstructured":"Steele JP, Shamash J, Evans MT, Gower NH, Tischkowitz MD, Rudd RM. Phase II study of vinorelbine in patients with malignant pleural mesothelioma. J Clin Oncol. 2000, 18:3912-7. 10.1200\/JCO.2000.18.23.3912","journal-title":"J Clin Oncol"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1016\/j.lungcan.2014.03.006","article-title":"Vinorelbine and gemcitabine as second- or third-line therapy for malignant pleural mesothelioma","volume":"84","author":"Zauderer MG","year":"2014","unstructured":"Zauderer MG, Kass SL, Woo K, Sima CS, Ginsberg MS, Krug LM. Vinorelbine and gemcitabine as second- or third-line therapy for malignant pleural mesothelioma. Lung Cancer. 2014, 84:271-4. 10.1016\/j.lungcan.2014.03.006","journal-title":"Lung Cancer"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/72463-the-rarest-of-the-rare-a-case-of-bap1-mutated-primary-peritoneal-mesothelioma","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T19:33:37Z","timestamp":1707507217000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/72463-the-rarest-of-the-rare-a-case-of-bap1-mutated-primary-peritoneal-mesothelioma"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9,29]]},"references-count":20,"URL":"https:\/\/doi.org\/10.7759\/cureus.18380","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2021,9,29]]}}}